{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:57:15Z","timestamp":1791107835312,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1796,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"abstract":"\n \n \n Polymorphisms in the<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n (interleukin-28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n in spontaneous and treatment-induced clearance following recent HCV infection. The Australian Trial in Acute Hepatitis C (ATAHC) was a study of the natural history and treatment of recent HCV, as defined by positive anti-HCV antibody, preceded by either acute clinical HCV infection within the prior 12 months or seroconversion within the prior 24 months. Factors associated with spontaneous and treatment-induced HCV clearance, including variations in<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n , were assessed. Among 163 participants, 132 were untreated (n = 52) or had persistent infection (infection duration \u226526 weeks) at treatment initiation (n = 80). Spontaneous clearance was observed in 23% (30 of 132 participants). In Cox proportional hazards analysis (without<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n ), HCV seroconversion illness with jaundice was the only factor predicting spontaneous clearance (adjusted hazards ratio = 2.86; 95% confidence interval = 1.24, 6.59;<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.014). Among participants with<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n genotyping (n = 102 of 163 overall and 79 of 132 for the spontaneous clearance population), rs8099917 TT homozygosity (versus GT\/GG) was the only factor independently predicting time to spontaneous clearance (adjusted hazard ratio = 3.78; 95% confidence interval = 1.04, 13.76;<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.044). Participants with seroconversion illness with jaundice were more frequently rs8099917 TT homozygotes than other (GG\/GT) genotypes (32% versus 5%,<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.047). Among participants adherent to treatment and who had<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n genotyping (n = 54), sustained virologic response was similar among TT homozygotes (18 of 29 participants, 62%) and those with GG\/GT genotype (16 of 25, 64%,<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.884).<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n During recent HCV infection, genetic variations in<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n region were associated with spontaneous but not treatment-induced clearance. Early therapeutic intervention could be recommended for individuals with unfavorable<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n genotypes. (Hepatology 2010;)<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hep.23850","type":"journal-article","created":{"date-parts":[[2010,7,29]],"date-time":"2010-07-29T15:13:43Z","timestamp":1280416423000},"page":"1216-1224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":137,"title":["Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection"],"prefix":"10.1097","volume":"52","author":[{"given":"Jason","family":"Grebely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayaprakash","family":"Suppiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Applegate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipa","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kaldor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20250312","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"R3-7-20250312","doi-asserted-by":"crossref","first-page":"123135","DOI":"10.1053\/j.gastro.2009.09.019","article-title":"Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.","volume":"138","author":"Dore","year":"2010","journal-title":"Gastroenterology"},{"key":"R4-7-20250312","doi-asserted-by":"crossref","first-page":"632638","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"R5-7-20250312","doi-asserted-by":"crossref","first-page":"14741482","DOI":"10.1086\/522608","article-title":"Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance.","volume":"196","author":"Wang","year":"2007","journal-title":"J Infect Dis"},{"key":"R6-7-20250312","doi-asserted-by":"crossref","first-page":"12161226","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult drug users: a prospective study of incident infection, resolution and reinfection.","volume":"200","author":"Page","year":"2009","journal-title":"J Infect Dis"},{"key":"R7-7-20250312","doi-asserted-by":"crossref","first-page":"103109","DOI":"10.1016\/j.antiviral.2009.02.203","article-title":"New insights into the immunopathogenesis of chronic hepatitis C.","volume":"82","author":"Diepolder","year":"2009","journal-title":"Antiviral Res"},{"key":"R8-7-20250312","doi-asserted-by":"crossref","first-page":"733756","DOI":"10.1007\/s00018-008-8270-4","article-title":"Immunological determinants of the outcomes from primary hepatitis C infection.","volume":"66","author":"Post","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"R9-7-20250312","doi-asserted-by":"crossref","first-page":"17451754","DOI":"10.1172\/JCI39133","article-title":"Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.","volume":"119","author":"Rehermann","year":"2009","journal-title":"J Clin Invest"},{"key":"R10-7-20250312","doi-asserted-by":"crossref","first-page":"321331","DOI":"10.1002\/hep.21902","article-title":"Acute hepatitis C virus infection: a chronic problem.","volume":"47","author":"Blackard","year":"2008","journal-title":"Hepatology"},{"key":"R11-7-20250312","doi-asserted-by":"crossref","first-page":"399401","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R12-7-20250312","doi-asserted-by":"crossref","first-page":"11001104","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy.","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"R13-7-20250312","doi-asserted-by":"crossref","first-page":"11051109","DOI":"10.1038\/ng.449","article-title":"Genomewide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C.","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"R14-7-20250312","doi-asserted-by":"crossref","first-page":"13381345","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study.","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"R15-7-20250312","doi-asserted-by":"crossref","first-page":"798801","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R16-7-20250312","doi-asserted-by":"crossref","first-page":"144150","DOI":"10.1017\/S0950268806006388","article-title":"Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users.","volume":"135","author":"Amin","year":"2007","journal-title":"Epidemiol Infect"},{"key":"R17-7-20250312","doi-asserted-by":"crossref","first-page":"14521457","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa2b.","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"R18-7-20250312","doi-asserted-by":"crossref","first-page":"250256","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha2b for acute hepatitis C infection: the HEPNET acuteHCVII study.","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"R19-7-20250312","doi-asserted-by":"crossref","first-page":"17211731","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virusspecific T cell response kinetics.","volume":"39","author":"Kamal","year":"2004","journal-title":"Hepatology"},{"key":"R20-7-20250312","doi-asserted-by":"crossref","first-page":"923931","DOI":"10.1002\/hep.21197","article-title":"Duration of peginterferon therapy in acute hepatitis C: a randomized trial.","volume":"43","author":"Kamal","year":"2006","journal-title":"Hepatology"},{"key":"R21-7-20250312","doi-asserted-by":"crossref","first-page":"263265","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps.","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R22-7-20250312","doi-asserted-by":"crossref","first-page":"18871898","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"R23-7-20250312","doi-asserted-by":"crossref","first-page":"967972","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C.","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"R24-7-20250312","first-page":"19321937","article-title":"IFNalpha regulates TLRdependent gene expression of IFNalpha, IFNbeta, IL28, and IL29.","volume":"174","author":"Siren","year":"2005","journal-title":"J Immunol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23850","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201010000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:08:06Z","timestamp":1741777686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201010000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23850","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}